Search research articles
Contact Us
Filters
Showing results (41-50 of 601) with videos related to
Page
of 61
Sort By:
Journal of Cancer Research and Clinical Oncology
|
October 18, 2003
The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review
S M Swain, P Vici
Oncology (Williston Park, N.Y.)
|
May 27, 2014
Pertuzumab: increasing the options
Raquel Nunes, Sandra M Swain
Cancers
|
March 29, 2023
Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets
Nadia Ashai, Sandra M Swain
JAMA Oncology
|
June 30, 2016
Cardiac Protection in HER2-Targeted Treatment: How Should We Measure New Strategies?
Ana Barac, Sandra M Swain
American Journal of Obstetrics and Gynecology
|
September 1, 1988
Systemic tocolysis for premature labor is associated with an increased incidence of pulmonary edema in the presence of maternal infection
C G Hatjis, M Swain
Cancer Investigation
|
June 13, 2014
Pertuzumab for the treatment of breast cancer
Filipa Lynce, Sandra M Swain
JAMA
|
October 17, 2013
Drug discount program
Sandra M Swain, Jeffery C Ward
The Oncologist
|
March 18, 2016
Enhanced Cardiac Testing in a Dual Anti-HER2 Regimen: What Have We Learned?
Michael S Ewer, Sandra M Swain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2005
Contralateral breast cancer: where does it all begin?
Suparna Bonthala Wedam, Sandra M Swain
Seminars in Oncology
|
December 20, 2005
Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR)
James J Lee, Sandra M Swain
Page
of 61
Search research articles
Search
Showing results (41-50 of 601) with videos related to
Sort By:
Page
of 61
Journal of Cancer Research and Clinical Oncology
|
October 18, 2003
The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review
S M Swain, P Vici
Oncology (Williston Park, N.Y.)
|
May 27, 2014
Pertuzumab: increasing the options
Raquel Nunes, Sandra M Swain
Cancers
|
March 29, 2023
Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets
Nadia Ashai, Sandra M Swain
JAMA Oncology
|
June 30, 2016
Cardiac Protection in HER2-Targeted Treatment: How Should We Measure New Strategies?
Ana Barac, Sandra M Swain
American Journal of Obstetrics and Gynecology
|
September 1, 1988
Systemic tocolysis for premature labor is associated with an increased incidence of pulmonary edema in the presence of maternal infection
C G Hatjis, M Swain
Cancer Investigation
|
June 13, 2014
Pertuzumab for the treatment of breast cancer
Filipa Lynce, Sandra M Swain
JAMA
|
October 17, 2013
Drug discount program
Sandra M Swain, Jeffery C Ward
The Oncologist
|
March 18, 2016
Enhanced Cardiac Testing in a Dual Anti-HER2 Regimen: What Have We Learned?
Michael S Ewer, Sandra M Swain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2005
Contralateral breast cancer: where does it all begin?
Suparna Bonthala Wedam, Sandra M Swain
Seminars in Oncology
|
December 20, 2005
Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR)
James J Lee, Sandra M Swain
Page
of 61